Mild Cognitive ImpairmentPhase 1/2NCT05289804
Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment
A Phase 1/2 study testing NITESGON, Lidocaine / Prilocaine Topical Cream and C5/C6 stimulation in people with Mild Cognitive Impairment and Memory Impairment, run by University of Dublin, Trinity College at 1 site in Ireland.
Trial summary
This study is designed as a prospective, double-blind, placebo-controlled, randomized parallel-group study that will be completed at the clinical research facility at St. James' Hospital and at Trinity College Dublin, Ireland. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Mild Cognitive Impairment, Memory Impairment, Memory Disorders in Old Age
- What is being tested?
- NITESGON, Lidocaine / Prilocaine Topical Cream and C5/C6 stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteIreland
- Study dates
- 1 Sep 2022to 1 Jan 2026
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ≥50 years
- Diagnosis of probable aMCI or mild AD
- Montreal Cognitive Assessment between 18-25
- Mini Mental State Examination score >21
- Stable AChl medication >3 months
- Adequate visual and auditory acuity
- Capacity to understand and sign informed consent
Who cannot join
- Any cause of cognitive decline or dementia that is not Alzheimer's disease related including parkinsonism related dementias, vascular dementia, fronto-temporal dementia.
- Enrolment in an ongoing investigational medicinal product study
- History in the past 2 years of epileptic seizures
- Any current major psychiatric disorder
- Evidence of brain damage, including significant trauma, stroke, hydrocephalus, intellectual disability, or serious neurological disorder.
- History of alcoholism or drug abuse within the last 12 months
- Medical devices not eligible for MRI scanning
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment: Study Protocol for a Prospective, Double-blind, Placebo-controlled, Randomized Controlled Trial
This study is designed as a prospective, double-blind, placebo-controlled, randomized parallel-group study that will be completed at the clinical research facility at St. James' Hospital and at Trinity College Dublin, Ireland. A total of 100 amnestic mild cognitive impairment (aMCI) patients will receive a (real or control) non-invasive transcutaneous electrical stimulation procedure. Patients will be assigned to one of four groups. One group will receive active stimulation, while the three groups will be control groups. One groups will be receive sham stimulation (inactive control), while a second group will receive active stimulation and local anesthesia and a third group will stimulate a different nerve (active control; same sensation different nerve). The investigators will include three control groups to verify that the effect is real and location specific and cannot be associated to a sensation effect. The investigators have opted to use a parallel-group design as it is unclear what the carry-over effect and/or wash-out period will be for stimulation. To eliminate subjective bias, all patients and the investigator testing the endpoint measures will be blinded to the type of intervention. The primary outcome, i.e. memory recall, will be determined by a word association task recorded immediately after stimulation, 7 days after stimulation, and 28 days after stimulation. The secondary outcomes is neurophysiological changes determined by resting state EEG, which will be assessed immediately before and after stimulation in the first session.
The investigators will conduct this study as follows:
- Screening aMCI patients.
- Randomly assigning aMCI patients to one of the four groups.
- Administering one session active stimulation (n = 25) or control (n = 25 in each of three control group) stimulation paired with a word-association task; administered by research assistant.
- Behavioral assessments after each of the three blocks of studying the word associations and neural measures immediately after the last session of Behavioral assessments (T0).
- Behavioral assessments at seven (T1) and 28 (T2) days after stimulation.
Read the detailed description
Patients 50 years of age and above with amnestic mild cognitive impairment (aMCI), will be recruited to the memory clinic at St. James and the Memory Assessment and Support Service Tallaght University Hospital. The investigators plan to include 100 English-speaking aMCI patients. To participate in this study, subjects should be able to provide an informed consent, have a confirmed aMCI diagnosis and have their medication stable for at least three months prior to baseline data collection. Prospective participants, who meet the criteria, will be sent an electronic copy of the consent form. Participants will only be asked to sign the consent form at the site after going over the form with the researcher where all aspects of the study protocol will be reviewed.
The study is designed to give us adequate power to detect clinically meaningful differences between the groups. Twenty individuals per group (total n = 80) would offer us a power of 80% to detect the difference between groups using Cohen's d estimation of effect size. A sample size of 80 will allow us to see a large effect size. Although The investigators do not expect attrition to be large, a dropout rate of no more than 10% is expected. This trial is longitudinal which could increase its drop-out rate. The investigators will thus oversample to a target sample size of 25 patients per group to assure that our power to detect effects is maintained. The overall sample will be 100. The investigators aim to recruit patients with aMCI and display pre-symptomatic signs of Alzheimer's disease (AD). An age ranging from 50 years and above is a good fit for this population.
The study consists of three in person sessions. Session 1 will consist of a word association memory task in which participants are instructed to memorize a subset of words. Participants will either receive active stimulation or control stimulation during the word-association task. Session 1 will also include demographic and mood related questionnaires, as well as EEG before and after memory testing. At the end of EEG testing, participants will fill out an exit questionnaire developed by Brunoni et al. to assess potential side-effects (headache, neck pain, scalp pain, tingling, itching, burning sensation, skin redness, sleepiness, trouble concentrating, mood changes) at the end of stimulation. One week after Session 1, Session 2 will take place. They will again complete the word association memory task. Three weeks after Session 2, Session 3 will take place and participants will complete the word association memory task and complete a blinding questionnaire at the end of the session.
During memory testing, participants will receive one of four interventions. Participants will encounter a second researcher who will take over for the first researcher in order to provide the blinded-stimulation protocol. They will be assigned randomly (like a flip of a coin) to one of four groups. Some groups will receive active stimulation and the other three groups will serve as controls. For sham stimulation, placement of the electrodes will be identical to active stimulation. A third group will receive stimulation, but with a topical skin anesthetic. For the fourth control group, the electrodes will be placed on the lower neck. For both the third and fourth control group, the current similar to active stimulation will be applied.
Participants will be paid at the end of the session and will be asked to sign a receipt of the money. If they successfully complete the study, they will be compensated for travel with 10 euros, if they wish to withdraw or are unable to proceed because of any in-eligibility in the in-person session, they will be compensated with 5 euros for travel.
All data will be managed using unique study codes, which will be used to code and file all electronic information, to protect participant confidentiality. To ensure privacy, all research files (e.g. screening, consent, questionnaires) will be stored in locked file cabinets in locked offices at Trinity. Electronic information (e.g. EEG and behavioral data) will be stored at a secure, password-protected, server at Trinity and all corresponding data analysis will be conducted at Trinity to ensure central and complete data protection. Subject names will not be published. Summary statistics will be performed on all variables and reported. The person processing the data will not be able to trace back the data to the individual. Data will contain a pseudonymised subject code and thus be de-identified. Pseudonymised data will be stored for 7 years as required by GDPR rules. After this personal and raw data will be deleted and the data will be anonymised. The processed data and group analysis will stored be indefinitely and will be shared through Trinity TARA Open Access database to promote Open Science. The key codes linking the participant names to the pseudonymised data will be stored in a secure Excel file in a secure USB by the Principal Investigator.
An intention-to-treat and per-protocol analysis will be performed. For the intention-to-treat analysis, the patient must successfully complete T0 and T1 assessments. For missing observations, the Last Observation Carried Forward (LOCF) approach will be used. Exclusion from the population will be finalized prior to database lock in a blinded manner. Memory recall during the word-association task will be assessed to determine memory performance. For EEG data, sLORETA statistical contrast maps will be calculated for the sham and active groups through multiple voxel-by-voxel comparisons in a logarithm of F-ratio. For transcutaneous electrical stimulation (TES) adverse events, a comparison will be conducted between the active and sham group using a one-way ANOVA with stimulation (active vs sham) as independent variable and adverse events as dependent variable. A Chi-square test will be conducted comparing actual stimulation (active vs sham) versus participants' expected stimulation (active vs sham) to determine if subjects were blinded to the experimental condition.
- Being tested
- NITESGON, Lidocaine / Prilocaine Topical Cream, C5/C6 stimulation, Sham NITESGON
- Keywords
- episodic memory, amnestic mild cognitive impairment, mild Alzheimer's disease, electrical stimulation, greater occipital nerve
- Medical subject headings
- Cognitive Dysfunction, Memory Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NITESGONDevice
Also called non-invasive transcutaneous electrical stimulation of the greater occipital nerve, transcutaneous electrical stimulation, tES, stimulation
NITESGON will be delivered by a specially developed, battery-driven, constant current stimulator via a pair of saline-soaked surface sponges on the scalp. One electrode each will be placed over the left and right C2 dermatomes.
NITESGON will first be switched on in a ramp-up fashion over 30 seconds. For active NITESGON, stimulation will occur during the word association task. For sham the current intensity (ramp down) will gradually be reduced (over 5 seconds) as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain.
Lidocaine / Prilocaine Topical CreamDrug
Also called lidocaine/prilocaine cream, local anesthetic
A topical skin anesthetic (lidocaine/prilocaine cream) will be used to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. This lidocaine/prilocaine preparation blocks sodium channels in peripheral nerves in the skin and thereby stabilizes the membrane potential and increases the threshold for firing an action potential.
C5/C6 stimulationDevice
The electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location.
Sham NITESGONDevice
Sham NITESGON
| Study group | Role | What they receive |
|---|---|---|
| Active NITESGON | Experimental | One electrode each will be placed over the left and right C2 dermatomes. A constant current will be applied during the word association task. Receives: Device: NITESGON |
| Sham NITESGON | Sham comparator | For sham NITESGON (inactive control), placement of the electrodes will be identical to active NITESGON. Current intensity (ramp down) will gradually be reduced as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain. Receives: Device: Sham NITESGON |
| Active NITESGON + local anesthesia | Active comparator | For active NITESGON + local anesthesia (active control; local nerve anesthesia group), patients will receive NITESGON, in combination with a topical skin anesthetic (lidocaine/prilocaine cream) to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. A current similar to active NITESGON will be applied. Receives: Device: NITESGON; Drug: Lidocaine / Prilocaine Topical Cream |
| Active C5/C6 | Active comparator | For the active C5/C6 group (active control; same sensation different nerve), the electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location. A current similar to active NITESGON will be applied. Receives: Device: C5/C6 stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Word association task performance immediately after NITEGON/sham
Patients will perform a Swahili-English word association task. Patients will be asked to learn a list of 50 Swahili-English word pairs. In a test phase, patients will be presented with the Swahili word and asked to type the correct English translation.
Measured: Patients will be tested immediately after NITESGON/sham (T0)
Word association task performance at 7 days
Patients will be asked to return for a follow-up test 7 days later. The test will be identical to the test phase from T0 timepoint.
Measured: 7 days after NITESGON/sham (T1)
Word association task performance at 28 days
Patients will be asked to return for a follow-up test 28 days after NITESGON/sham. The test will be identical to the test phase from T0 timepoint.
Measured: 28 days after NITESGON/sham (T2)
Secondary outcomes (1)
EEG gamma oscillations
Rest-state EEG will be collected immediately before and after NITESGON/sham (T0) and will be correlated with the recall of the word-association task 7 (T1) and 28 (T2) days after NITESGON.
Measured: Resting state EEG will be collected immediately before and immediately after NITESGON/sham.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Mar 2022
- Study start1 Sep 2022
- Primary completion31 Dec 2025
- Study completion1 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Mild Cognitive ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The investigators have opted to use a parallel-group design as it is unclear what the carry-over effect and/or wash-out period will be for NITESGON. Patients will be randomized after the baseline evaluation and will be assigned to receive one of the four possible types of NITESGON. To eliminate subjective bias, all patients and the investigator testing the endpoint measures will be blinded to the type of intervention.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Dublin, Trinity College
- Sponsor type
- University, hospital or other
- Collaborators
- Alzheimer's Association
- Responsible party
- Principal investigator, Sven Vanneste, University of Dublin, Trinity College
- Investigators
- Sven Vanneste, PhD, Principal investigator, University of Dublin, Trinity College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05289804
- Sponsor's protocol ID
- SPREC102021-23
- Other IDs
- AARG-21-848486
- Status last verified
- Jan 2026
- First submitted
- 22 Feb 2022
- Last updated
- 26 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. Int J Neuropsychopharmacol. 2011 Sep;14(8):1133-45. doi: 10.1017/S1461145710001690. Epub 2011 Feb 15.
PubMed 21320389Luckey AM, McLeod SL, Robertson IH, To WT, Vanneste S. Greater Occipital Nerve Stimulation Boosts Associative Memory in Older Individuals: A Randomized Trial. Neurorehabil Neural Repair. 2020 Nov;34(11):1020-1029. doi: 10.1177/1545968320943573. Epub 2020 Sep 23.
PubMed 32964776Vanneste S, Mohan A, Yoo HB, Huang Y, Luckey AM, McLeod SL, Tabet MN, Souza RR, McIntyre CK, Chapman S, Robertson IH, To WT. The peripheral effect of direct current stimulation on brain circuits involving memory. Sci Adv. 2020 Nov 4;6(45):eaax9538. doi: 10.1126/sciadv.aax9538. Print 2020 Nov.
PubMed 33148657Adcock KS, Lawlor B, Robertson IH, Vanneste S. Diminishing accelerated long-term forgetting in mild cognitive impairment: Study protocol for a prospective, double-blind, placebo-controlled, randomized controlled trial. Contemp Clin Trials Commun. 2022 Sep 2;30:100989. doi: 10.1016/j.conctc.2022.100989. eCollection 2022 Dec.
PubMed 36117569
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment: Study Protocol for a Prospective, Double-blind, Placebo-controlled, Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT05289804
- Acronym / sponsor ID
- SPREC102021-23
- Keywords
- episodic memory, amnestic mild cognitive impairment, mild Alzheimer's disease, electrical stimulation, greater occipital nerve
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- University of Dublin, Trinity CollegeUniversity, hospital or other
- Collaborators
- Alzheimer's Association
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 1 Jan 2026 (actual)
- First posted
- 21 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed as a prospective, double-blind, placebo-controlled, randomized parallel-group study that will be completed at the clinical research facility at St. James' Hospital and at Trinity College Dublin, Ireland. A total of 100 amnestic mild cognitive impairment (aMCI) patients will receive a (real or control) non-invasive transcutaneous electrical stimulation procedure. Patients will be assigned to one of four groups. One group will receive active stimulation, while the three groups will be control groups. One groups will be receive sham stimulation (inactive control), while a second group will receive active stimulation and local anesthesia and a third group will stimulate a different nerve (active control; same sensation different nerve). The investigators will include three control groups to verify that the effect is real and location specific and cannot be associated to a sensation effect. The investigators have opted to use a parallel-group design as it is unclear what the carry-over effect and/or wash-out period will be for stimulation. To eliminate subjective bias, all patients and the investigator testing the endpoint measures will be blinded to the type of intervention. The primary outcome, i.e. memory recall, will be determined by a word association task recorded immediately after stimulation, 7 days after stimulation, and 28 days after stimulation. The secondary outcomes is neurophysiological changes determined by resting state EEG, which will be assessed immediately before and after stimulation in the first session.
The investigators will conduct this study as follows:
- Screening aMCI patients.
- Randomly assigning aMCI patients to one of the four groups.
- Administering one session active stimulation (n = 25) or control (n = 25 in each of three control group) stimulation paired with a word-association task; administered by research assistant.
- Behavioral assessments after each of the three blocks of studying the word associations and neural measures immediately after the last session of Behavioral assessments (T0).
- Behavioral assessments at seven (T1) and 28 (T2) days after stimulation.
Detailed description
Patients 50 years of age and above with amnestic mild cognitive impairment (aMCI), will be recruited to the memory clinic at St. James and the Memory Assessment and Support Service Tallaght University Hospital. The investigators plan to include 100 English-speaking aMCI patients. To participate in this study, subjects should be able to provide an informed consent, have a confirmed aMCI diagnosis and have their medication stable for at least three months prior to baseline data collection. Prospective participants, who meet the criteria, will be sent an electronic copy of the consent form. Participants will only be asked to sign the consent form at the site after going over the form with the researcher where all aspects of the study protocol will be reviewed.
The study is designed to give us adequate power to detect clinically meaningful differences between the groups. Twenty individuals per group (total n = 80) would offer us a power of 80% to detect the difference between groups using Cohen's d estimation of effect size. A sample size of 80 will allow us to see a large effect size. Although The investigators do not expect attrition to be large, a dropout rate of no more than 10% is expected. This trial is longitudinal which could increase its drop-out rate. The investigators will thus oversample to a target sample size of 25 patients per group to assure that our power to detect effects is maintained. The overall sample will be 100. The investigators aim to recruit patients with aMCI and display pre-symptomatic signs of Alzheimer's disease (AD). An age ranging from 50 years and above is a good fit for this population.
The study consists of three in person sessions. Session 1 will consist of a word association memory task in which participants are instructed to memorize a subset of words. Participants will either receive active stimulation or control stimulation during the word-association task. Session 1 will also include demographic and mood related questionnaires, as well as EEG before and after memory testing. At the end of EEG testing, participants will fill out an exit questionnaire developed by Brunoni et al. to assess potential side-effects (headache, neck pain, scalp pain, tingling, itching, burning sensation, skin redness, sleepiness, trouble concentrating, mood changes) at the end of stimulation. One week after Session 1, Session 2 will take place. They will again complete the word association memory task. Three weeks after Session 2, Session 3 will take place and participants will complete the word association memory task and complete a blinding questionnaire at the end of the session.
During memory testing, participants will receive one of four interventions. Participants will encounter a second researcher who will take over for the first researcher in order to provide the blinded-stimulation protocol. They will be assigned randomly (like a flip of a coin) to one of four groups. Some groups will receive active stimulation and the other three groups will serve as controls. For sham stimulation, placement of the electrodes will be identical to active stimulation. A third group will receive stimulation, but with a topical skin anesthetic. For the fourth control group, the electrodes will be placed on the lower neck. For both the third and fourth control group, the current similar to active stimulation will be applied.
Participants will be paid at the end of the session and will be asked to sign a receipt of the money. If they successfully complete the study, they will be compensated for travel with 10 euros, if they wish to withdraw or are unable to proceed because of any in-eligibility in the in-person session, they will be compensated with 5 euros for travel.
All data will be managed using unique study codes, which will be used to code and file all electronic information, to protect participant confidentiality. To ensure privacy, all research files (e.g. screening, consent, questionnaires) will be stored in locked file cabinets in locked offices at Trinity. Electronic information (e.g. EEG and behavioral data) will be stored at a secure, password-protected, server at Trinity and all corresponding data analysis will be conducted at Trinity to ensure central and complete data protection. Subject names will not be published. Summary statistics will be performed on all variables and reported. The person processing the data will not be able to trace back the data to the individual. Data will contain a pseudonymised subject code and thus be de-identified. Pseudonymised data will be stored for 7 years as required by GDPR rules. After this personal and raw data will be deleted and the data will be anonymised. The processed data and group analysis will stored be indefinitely and will be shared through Trinity TARA Open Access database to promote Open Science. The key codes linking the participant names to the pseudonymised data will be stored in a secure Excel file in a secure USB by the Principal Investigator.
An intention-to-treat and per-protocol analysis will be performed. For the intention-to-treat analysis, the patient must successfully complete T0 and T1 assessments. For missing observations, the Last Observation Carried Forward (LOCF) approach will be used. Exclusion from the population will be finalized prior to database lock in a blinded manner. Memory recall during the word-association task will be assessed to determine memory performance. For EEG data, sLORETA statistical contrast maps will be calculated for the sham and active groups through multiple voxel-by-voxel comparisons in a logarithm of F-ratio. For transcutaneous electrical stimulation (TES) adverse events, a comparison will be conducted between the active and sham group using a one-way ANOVA with stimulation (active vs sham) as independent variable and adverse events as dependent variable. A Chi-square test will be conducted comparing actual stimulation (active vs sham) versus participants' expected stimulation (active vs sham) to determine if subjects were blinded to the experimental condition.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
- Model description
- The investigators have opted to use a parallel-group design as it is unclear what the carry-over effect and/or wash-out period will be for NITESGON. Patients will be randomized after the baseline evaluation and will be assigned to receive one of the four possible types of NITESGON. To eliminate subjective bias, all patients and the investigator testing the endpoint measures will be blinded to the type of intervention.
| Arm | Type | Receives |
|---|---|---|
| Active NITESGON | Experimental | Device: NITESGONOne electrode each will be placed over the left and right C2 dermatomes. A constant current will be applied during the word association task. |
| Sham NITESGON | Sham comparator | Device: Sham NITESGONFor sham NITESGON (inactive control), placement of the electrodes will be identical to active NITESGON. Current intensity (ramp down) will gradually be reduced as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain. |
| Active NITESGON + local anesthesia | Active comparator | Device: NITESGON, Drug: Lidocaine / Prilocaine Topical CreamFor active NITESGON + local anesthesia (active control; local nerve anesthesia group), patients will receive NITESGON, in combination with a topical skin anesthetic (lidocaine/prilocaine cream) to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. A current similar to active NITESGON will be applied. |
| Active C5/C6 | Active comparator | Device: C5/C6 stimulationFor the active C5/C6 group (active control; same sensation different nerve), the electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location. A current similar to active NITESGON will be applied. |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- ≥50 years
- Diagnosis of probable aMCI or mild AD
- Montreal Cognitive Assessment between 18-25
- Mini Mental State Examination score >21
- Stable AChl medication >3 months
Key exclusion criteria (7 listed)
- Any cause of cognitive decline or dementia that is not Alzheimer's disease related including parkinsonism related dementias, vascular dementia, fronto-temporal dementia.
- Enrolment in an ongoing investigational medicinal product study
- History in the past 2 years of epileptic seizures
- Any current major psychiatric disorder
- Evidence of brain damage, including significant trauma, stroke, hydrocephalus, intellectual disability, or serious neurological disorder.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NITESGONAlso: non-invasive transcutaneous electrical stimulation of the greater occipital nerve, transcutaneous electrical stimulation, tES, stimulationNITESGON will be delivered by a specially developed, battery-driven, constant current stimulator via a pair of saline-soaked surface sponges on the scalp. One electrode each will be placed over the left and right C2 dermatomes. NITESGON will first be switched on in a ramp-up fashion over 30 seconds. For active NITESGON, stimulation will occur during the word association task. For sham the current intensity (ramp down) will gradually be reduced (over 5 seconds) as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain. | Device | Active NITESGON, Active NITESGON + local anesthesia |
| Lidocaine / Prilocaine Topical CreamAlso: lidocaine/prilocaine cream, local anestheticA topical skin anesthetic (lidocaine/prilocaine cream) will be used to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. This lidocaine/prilocaine preparation blocks sodium channels in peripheral nerves in the skin and thereby stabilizes the membrane potential and increases the threshold for firing an action potential. | Drug | Active NITESGON + local anesthesia |
| C5/C6 stimulationThe electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location. | Device | Active C5/C6 |
| Sham NITESGONSham NITESGON | Device | Sham NITESGON |
Primary outcome
Word association task performance immediately after NITEGON/sham
Time frame: Patients will be tested immediately after NITESGON/sham (T0)
Patients will perform a Swahili-English word association task. Patients will be asked to learn a list of 50 Swahili-English word pairs. In a test phase, patients will be presented with the Swahili word and asked to type the correct English translation.
Word association task performance at 7 days
Time frame: 7 days after NITESGON/sham (T1)
Patients will be asked to return for a follow-up test 7 days later. The test will be identical to the test phase from T0 timepoint.
Word association task performance at 28 days
Time frame: 28 days after NITESGON/sham (T2)
Patients will be asked to return for a follow-up test 28 days after NITESGON/sham. The test will be identical to the test phase from T0 timepoint.
1 secondary outcome
EEG gamma oscillations
Time frame: Resting state EEG will be collected immediately before and immediately after NITESGON/sham.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2026.
- Background: PubMed 21320389Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. Int J Neuropsychopharmacol. 2011 Sep;14(8):1133-45. doi: 10.1017/S1461145710001690. Epub 2011 Feb 15.
- Background: PubMed 32964776Luckey AM, McLeod SL, Robertson IH, To WT, Vanneste S. Greater Occipital Nerve Stimulation Boosts Associative Memory in Older Individuals: A Randomized Trial. Neurorehabil Neural Repair. 2020 Nov;34(11):1020-1029. doi: 10.1177/1545968320943573. Epub 2020 Sep 23.
- Background: PubMed 33148657Vanneste S, Mohan A, Yoo HB, Huang Y, Luckey AM, McLeod SL, Tabet MN, Souza RR, McIntyre CK, Chapman S, Robertson IH, To WT. The peripheral effect of direct current stimulation on brain circuits involving memory. Sci Adv. 2020 Nov 4;6(45):eaax9538. doi: 10.1126/sciadv.aax9538. Print 2020 Nov.
- Derived from this study: PubMed 36117569Adcock KS, Lawlor B, Robertson IH, Vanneste S. Diminishing accelerated long-term forgetting in mild cognitive impairment: Study protocol for a prospective, double-blind, placebo-controlled, randomized controlled trial. Contemp Clin Trials Commun. 2022 Sep 2;30:100989. doi: 10.1016/j.conctc.2022.100989. eCollection 2022 Dec.
- Individual participant dataSharing planned: No
Related trials for Mild Cognitive Impairment
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingPhase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Parkinson's Disease, Dementia
Recruiting
Buddy-Up Dyadic Physical Activity Program for Persons With Dementia and Family Caregivers
Cognitive Impairment, Mild, Dementia, Mild
Recruiting
ENACT Program on Auditory Perception and Function, Cognitive Function and Health-related Quality of Life
Hearing Loss, Cognitive Impairment, Mild
Enrolling by invitationPhase 2
Tau PET Outcomes With Anti-amyloid Immunotherapies
Cognitive Impairment, Mild, Dementia, Mild
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sven Vanneste, PhD principal investigator
University of Dublin, Trinity College
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing NITESGON, Lidocaine / Prilocaine Topical Cream and C5/C6 stimulation in people with Mild Cognitive Impairment and Memory Impairment, run by University of Dublin, Trinity College at 1 site in Ireland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Word association task performance immediately after NITEGON/sham (time frame: Patients will be tested immediately after NITESGON/sham (T0)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05289804, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.